7 Undervalued Pharmaceuticals Stocks for Tuesday, October 22
Discover the top 7 undervalued Pharmaceuticals stocks for Tuesday, October 22 based on AAII’s Stock Grades.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company’s product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Commentary & Analysis
Is Artelo Biosciences Inc (ARTL) Stock a Good Investment?
Learn more about Artelo Biosciences Inc's (ARTL) stock grades for Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.Jack Gilleland
Financial Summary
| Share Statistics | ARTL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3.3 | $618.0 | 2% |
|
| Shares Out (Mil) | 2.7 | 44.8 | 9% |
|
| Institutional Ownership | 95.2% | 85.3% | 67% |
|
| Float (Mil) | 3.5 | 47.4 | 9% |
|
| Beta | -0.07 | 0.70 | 5% |
|
| Avg Daily Volume (000s) | 876 | 390 | 68% |
|
| Price Change (52-week) |
(97.6%) | 68.6% | 2% |
|
| Growth | ARTL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (11.8%) | (1.6%) | 27% |
|
| EPS (5yr) | 19.0% | 14.9% | 66 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.8%) | (14.9%) | 47% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ARTL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $291 | na |
|
| Net Income (TTM) (Mil) | ($13) | ($11) | 27% |
|
| EPS (TTM) | ($11.379) | ($0.700) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($13) | ($6) | 18% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($1) | $450 | 3% |
|
| Valuation | ARTL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.60 | 2.78 | 10% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ARTL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.0% | na |
|
| Net Margin | na | (2.3%) | na |
|
| ROA | (234.3%) | (22.4%) | 2% |
|
| ROE | (705.7%) | (20.2%) | 0% |
|
| Liabilities to Assets | 22.6% | 32.2% | 15% |
|
| F-Score | 3 | 3 | 18% |
|
Artelo Biosciences, Inc. did not pass any screens on 8/20/2026.
